Ardelyx
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 267
- Market Cap
- $1.4B
- Website
- http://www.ardelyx.com
- Introduction
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and d...
4-Week, Multi-Center, Randomized, Db-Blind, Placebo-Controlled, Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
- Conditions
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 72
- Registration Number
- NCT06553547
- Locations
- 🇺🇸
Florida Pharmaceutical Research and Associates, Inc., South Miami, Florida, United States
An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 7
- Registration Number
- NCT06203444
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
🇺🇸DDSI, Oklahoma City, Oklahoma, United States
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 150
- Registration Number
- NCT05905926
- Locations
- 🇺🇸
Advantage Clinical Trials, Bronx, New York, United States
🇺🇸Frontier Clinical Research, Kingwood, West Virginia, United States
🇺🇸G & L Research, LLC, Foley, Alabama, United States
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
- Conditions
- Interventions
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 180
- Registration Number
- NCT05643534
- Locations
- 🇺🇸
Proactive Clinical Research, El Paso, Texas, United States
🇺🇸G & L Research, LLC, Foley, Alabama, United States
🇺🇸Eclipse Clinical Research, Tucson, Arizona, United States
A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 109
- Registration Number
- NCT04780841
- Locations
- 🇺🇸
Horizon Research Group LLC, Coral Gables, Florida, United States
🇺🇸Panax Clinical Research LLC, Miami Lakes, Florida, United States
🇺🇸NW Louisiana Nephrology Assoc, Shreveport, Louisiana, United States
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 333
- Registration Number
- NCT04549597
- Locations
- 🇺🇸
South Florida Research Institute, Lauderdale Lakes, Florida, United States
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 172
- Registration Number
- NCT03988920
- Locations
- 🇺🇸
Ardelyx Site #509, Houston, California, United States
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 236
- Registration Number
- NCT03824587
- Locations
- 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸Mountain Kidney & Hypertension Associates, P.A., Asheville, North Carolina, United States
🇺🇸California Institute of Renal Research - Chula Vista, Chula Vista, California, United States
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 1559
- Registration Number
- NCT03427125
- Locations
- 🇺🇸
Site 529, Bronx, New York, United States
🇺🇸Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 60
- Registration Number
- NCT03018067
- Locations
- 🇺🇸
Capital Nephrology Associates, PA, Cary, North Carolina, United States